Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children
-
Published Date:October 3, 2008
-
Status:superseded
-
Source:MMWR. Morbidity and mortality weekly report. 2008; 57(39):1079-80.
-
Language:English
-
Details:
-
Alternative Title:MMWR. Morbidity and mortality weekly report
-
Corporate Authors:
-
Description:On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, Swiftwater, Pennsylvania), for use as a four-dose series in infants and children at ages 2, 4, 6, and 15-18 months. This report summarizes the indications for Pentacel and provides guidance from the Advisory Committee on Immunization Practices (ACIP) for its use.
-
Subject:
-
-
Pubmed ID:18830213
-
Document Type:
-
-
Main Document Checksum:
-
Supporting Files:No Additional Files
No Related Documents.
You May Also Like: